Diosynth

From Wikipedia, the free encyclopedia
Not to be confused with Russell Marker's company, which eventually became part of Gedeon Richter Ltd..

Diosynth, or Fujifilm Diosynth Biotechnologies (FDB), is a company that develops and offers manufacturing processes for active ingredients for pharmaceutical companies.[1]

History[]

The company started in Oss, Netherlands[2] in 1923 with the extraction of insulin from bovine pancreata, and porcine insulin extraction in 1930, both of which are still part of their main products.[3][4][5] In January 2005, the company became a part of Organon, one of its sister companies in the Akzo Nobel pharma group.[6] Along with its sister companies Organon and Intervet were sold to Schering-Plough in March 2007 by Akzo Nobel.[7] Following the mergers of Schering-Plough with Merck & Co. (MSD) on March 9, 2009,[8] the company was part of the MSD Nutritionals products company, belonging to the MSD group.[9] In April 2011, the company was sold to Fujifilm and Fujifilm Diosynth Biotechnologies was formed.[10] On December 18, 2014, Fujifilm Diosynth Biotechnologies acquired Kalon Biotherapeutic Technologies in College Station, TX, which became Fujifilm Diosynth Biotechnologies Texas, LLC.[11]

In March 2020, Fujifilm Diosynth Biotechnologies named Martin Meeson the company's new CEO. He will be taking over from Steve Bagshaw who is set to retire and become a non-executive chairman.[12]

Subject to regulatory approval, at least 60 million doses of the Novavax COVID-19 vaccine will be manufactured for the UK government from 2021 by Fujifilm Diosynth Biotechnologies at its Billingham site.[13][14]

References[]

  1. ^ "Products and Technologies" (PDF). Diosynth. 2006. Archived from the original (PDF) on 21 October 2006. Retrieved 19 June 2010.
  2. ^ "Diosynth BV". Top 500.de. Retrieved 19 June 2010.
  3. ^ "Diosynth Company History". Diosynth. Archived from the original on 11 May 2010. Retrieved 19 June 2010.
  4. ^ "Diosynth and Biochemistry". Diosynth. Archived from the original on 18 December 2003. Retrieved 19 June 2010.
  5. ^ "Diosynth-Usine Saint Charles, France-Insulin Extraction Plant". Vanelk. Retrieved 22 June 2010.
  6. ^ "81 Years of Organon at a Glance". Organon. Archived from the original on 9 March 2005. Retrieved 19 June 2010.
  7. ^ "Schering-Plough Acquires Organon BioSciences". Medical Net News. 20 November 2007. Retrieved 19 June 2010.
  8. ^ Singer (10 March 2010). "Merck to Buy Schering-Plough for $41 Billion". New York Times. Retrieved 19 June 2010.
  9. ^ Communication from one employee, no reference found on the web site, but a presentation of Diosynth france company(modified april.2012)
  10. ^ "Company History". Fujifilm. Retrieved 2013-12-04.
  11. ^ "Fujifilm Completes Acquisition of Kalon Biotherapeutics". Fujifilm. Retrieved 2015-07-14.
  12. ^ "New CEO takes over as Fujifilm Diosynth Biotechnologies expands". FiercePharma. Retrieved 2020-03-11.
  13. ^ Boseley, Sarah; Davis, Nicola (28 January 2021). "Novavax Covid vaccine shown to be nearly 90% effective in UK trial". The Guardian. Retrieved 29 January 2021.
  14. ^ Brown, Mike (14 August 2020). "60m doses of new covid-19 vaccine could be made in Billingham - and be ready for mid-2021". TeesideLive. Reach. Retrieved 29 January 2021.
Retrieved from ""